In this first part of an interview with The American Journal of Managed Care®, Julia Rotow, MD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the critical need to test for biomarkers ...
The definition of comprehensive non-small cell lung cancer (NSCLC) testing is rapidly evolving with new biomarkers and therapies, according to Julia Rotow, MD, creating added challenges for community ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Julia Rotow, MD: ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Julia Rotow, MD: ...
Please provide your email address to receive an email when new articles are posted on . MADRID — In this video, Julia Rotow, MD, highlighted positive OS data from the KEYNOTE-671 study of a ...
Please provide your email address to receive an email when new articles are posted on . Biomarker testing in patients with lung cancer allows for the potential of personalized therapy options that may ...
Glecirasib, a highly selective covalent oral inhibitor of KRAS G12C, demonstrated promising efficacy in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC), according ...
The selection of a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) has become increasingly complex in recent years with available options now including ...
Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results